[Influence of cardiac agents on the diastolic irritability of the ventricular myocardium. Consequences for pacemaker therapy].
D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D004071:Digitalis Glycosides / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D010138:Pacemaker, Artificial; D010672:Phenytoin / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013268:Stimulation, Chemical; D014700:Verapamil / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D000404:Ajmaline; D010672:Phenytoin; D008012:Lidocaine; D011433:Propranolol; D014700:Verapamil; D011342:Procainamide
Der Einfluss herzwirksamer Pharmaka auf die diastolische Erregbarkeit des Ventrikelmyokards. Konsequenzen für die Schrittmachertherapie